Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes - Agropolis Accéder directement au contenu
Article Dans Une Revue Journal of Thoracic Oncology Année : 2008

Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes

Résumé

Hypothesis: Lung cancer remains the leading cause of cancer-related mortality worldwide. Currently known serum markers do not efficiently diagnose lung cancer at early stage. Methods: In the present study, we developed a serum proteomic fingerprinting approach Coupled with a three-step classification method to address two important clinical questions: (i) to determine whether or not proteomic profiling differs between lung cancer and benign lung diseases in a population of smokers and (ii) to assess the prognostic impact of this profiling in lung cancer. Proteomic spectra were obtained from 170 pathologically confirmed lung cancer or smoking patients with benign chronic lung disease serum samples. Results: Among the 228 protein peaks differentially expressed in the whole Population, 88 differed significantly between lung cancer patients and benign lung disease. with area under the curve diagnostic values ranging from 0.63 to 0.84. Multiprotein classifiers based on differentially expressed peaks allowed the classification of lung cancer and benign disease with an area under the curve ranging from 0.991 to 0.994. Using a cross-validation methodology, diagnostic accuracy was 93.1% (sensitivity 94.3%, specificity 85.9%), and more than 90% of the stage I/II lung cancers were correctly classified. Finally, in the prognosis part of the Study, a 4628 Da protein was found to be significantly and independently associated with prognosis in advanced stage non-small cell lung cancer patients (p = 0.0005). Conclusions: The potential markers that we identified through proteomic fingerprinting Could accurately classify lung cancers ill a high-risk population and predict survival in a non-small cell lung cancer population.

Mots clés

Fichier non déposé

Dates et versions

hal-02660550 , version 1 (30-05-2020)

Identifiants

  • HAL Id : hal-02660550 , version 1
  • PRODINRA : 196456
  • WOS : 000258447300006

Citer

W. Jacot, L. Lhermitte, N. Dossat, J. L. Pujol, Nicolas Molinari, et al.. Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes. Journal of Thoracic Oncology, 2008, 3 (8), pp.840-850. ⟨hal-02660550⟩
10 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More